Zitong Financial App News, China Medical Group (08225) announced that on November 5, 2021, Science magazine reported that Pfizer Inc's combination of antiviral drugs could reduce high-risk death and hospitalization by 89%, while Merck's drug Molnupiravir, which was first officially announced, reduced the hospitalization rate and mortality rate to 50%. Pfizer Inc's shares rose 10.7 per cent before trading in recent days.
Pfizer Inc Paxlovid consists of two components: PF-07321332 and ritonavir. Among them, ritonavir is a drug that the group participated in research and long-term benefits in the past few years. Maikexin, the raw material and oral liquid of ritonavir, has been registered and approved by the affiliated company Wanquan Pharmaceutical and the State Drug Administration of China (national drug standard H20051019).
The Group's "RWS Wanquan Center" has a grand plan to re-screen and organize existing drugs through big data's real clinical research to find the best treatment. In addition to finding that a number of drugs such as Ritonavir have an inhibitory effect on novel coronavirus (2019-nCoV), it also includes how drugs such as Yueting reduce the death of COVID-19 in smokers, as well as the prevention and treatment of depression and allergic diseases caused by COVID-19.
The announcement said that with regard to the reduction of nearly 90% of novel coronavirus's death, COVID-19 will coexist with human beings for a long time, which will also bring long-term drug demand. It is believed that the production and manufacturing of the affiliated enterprises of the group and the continuous clinical research and promotion of the group will bring considerable income to the company in the long term.